Narrow search
Showing 1 - 10 of 453
Cover Image
Longitudinal analysis of generic substitution
Dalen, Dag Morten; Locatelli, Marilena; Strøm, Steinar - 2010
). The generics are Provastatine and Simastatine. The model accounts for taste persistence and is estimated on panel data. We … transition from generics to brand and likewise an increase in the generic price will reduce the transition from brand to generics. …
Persistent link: https://www.econbiz.de/10010275018
Cover Image
The Design of Insurance Coverage for Medical Products under Imperfect Competition
Bardey, David; Cremer, Helmuth; Lozachmeur, Jean-Marie - 2015
are considered. The insurance contract specifies two types of copayments: an ad valorem coinsurance rate and a specific …
Persistent link: https://www.econbiz.de/10010500394
Cover Image
Coinsurance vs. Copayments: Reimbursement Rules for a Monopolistic Medical Product with Competitive Health Insurers
Cremer, Helmuth; Lozachmeur, Jean-Marie - 2021
copayments (specific reimbursements). We show that the induced equilibrium with copayments involves a lower producer price and a …
Persistent link: https://www.econbiz.de/10012599247
Cover Image
The Impact of R&D Cooperations on Drug Variety Offered on the Market. Evidence from the Pharmaceutical Industry
Banerjee, Tannista; Siebert, Ralph - 2014
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010328831
Cover Image
Dynamic Effects of Licensing and Knowledge Transfer Across Research Stages : Evidence from the Pharmaceutical Industry
Tian, Zhili - 2020
In the pharmaceutical industry, firms frequently engage in licensing agreements to overcome innovation challenges and keep up with the pace of developing new drugs. Licensing helps firms jointly develop new drugs and acquire external knowledge, which helps improve their internal drug development...
Persistent link: https://www.econbiz.de/10012832198
Cover Image
Pricing the Pharmaceuticals When the Ability to Pay Differs : Taking Vertical Equity Seriously
Kanniainen, Vesa - 2020
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. Therefore, the paper analyzes the public insurance of the pharmaceutical products in terms of price controls and the socially optimal third-degree price discrimination. It characterizes...
Persistent link: https://www.econbiz.de/10012843430
Cover Image
Price Regulation and Parallel Imports of Pharmaceuticals
Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - 2015
This paper studies the effects of price regulation and parallel imports in the on-patent pharmaceutical market. In a theory model where the producer price is subject to bargaining between the brand-name producer and a distributor, we show that the effects of stricter price regulation crucially...
Persistent link: https://www.econbiz.de/10011307132
Cover Image
Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment
Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - 2010
We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using … prices and market shares of brand-names and generics. Then, we exploit a detailed panel data set at product level covering …-savings, and that patients' copayments decrease despite the extra surcharges under RP. …
Persistent link: https://www.econbiz.de/10010274913
Cover Image
The Patent Buyout Price for Human Papilloma Virus (HPV) Vaccine and the Ratio of R&D Costs to the Patent Value
Songane, Mario; Grossmann, Volker - 2020
Human papillomavirus (HPV) is responsible for almost all of the 570,000 new cases of cervical cancer and approximately 311,000 deaths per year. HPV vaccination is an integral component of the World Health Organization’s (WHO) global strategy to fight the disease. However, high vaccine prices...
Persistent link: https://www.econbiz.de/10012269558
Cover Image
Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform
Brekke, Kurt R.; Canta, Chiara; Straume, Odd Rune - 2022
entry by generic producers. Reference pricing shifts demand towards generics but also induces the branded producer to become …
Persistent link: https://www.econbiz.de/10013353465